Enliven Therapeutics (ELVN) Operating Expenses (2019 - 2026)
Enliven Therapeutics (ELVN) posted Operating Expenses of $27.8 million for Q1 2026, down 18.85% sequentially from $34.3 million in Q4 2025, and down 12.21% YoY from $31.7 million in Q1 2025.
Enliven Therapeutics (ELVN) Operating Expenses (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $27.8 million in Q1 2026.
- Quarterly Operating Expenses fell 12.21% year-over-year to $27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.8 million (up 5.01% YoY) and the FY2025 annual result came in at $119.7 million, up 14.45% from the prior year.
- Operating Expenses declined to $27.8 million in Q1 2026 per ELVN's latest filing, from $34.3 million in the prior quarter.
- Over five years, Operating Expenses peaked at $34.3 million in Q4 2025 and troughed at $8.7 million in Q1 2022.
- A 5-year average of $22.0 million and a median of $24.6 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses slumped 31.54% in 2022, then jumped 123.64% in 2023.
- Over 5 years, Operating Expenses stood at $10.2 million in 2022, then soared by 123.64% to $22.7 million in 2023, then rose by 18.33% to $26.9 million in 2024, then rose by 27.47% to $34.3 million in 2025, then dropped by 18.85% to $27.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $27.8 million, $34.3 million, and $25.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 37.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.21 Mn |
| Mar 31, 2026 | 27.82 Mn |
| Dec 31, 2025 | 34.29 Mn |
| Sep 30, 2025 | 25.10 Mn |
| Jun 30, 2025 | 28.58 Mn |
| Mar 31, 2025 | 31.69 Mn |
| Dec 31, 2024 | 26.90 Mn |
| Sep 30, 2024 | 27.07 Mn |
| Jun 30, 2024 | 24.60 Mn |
| Mar 31, 2024 | 25.99 Mn |
| Dec 31, 2023 | 22.73 Mn |
| Sep 30, 2023 | 24.25 Mn |
| Jun 30, 2023 | 20.13 Mn |
| Mar 31, 2023 | 16.42 Mn |
| Dec 31, 2022 | 10.16 Mn |
| Sep 30, 2022 | 10.93 Mn |
| Jun 30, 2022 | 9.02 Mn |
| Mar 31, 2022 | 8.68 Mn |
| Dec 31, 2021 | 14.33 Mn |
| Sep 30, 2021 | 13.66 Mn |